Condition (MeSH)
Deltaretrovirus Infections
ClinicalTrials.gov lists 31 trials for Deltaretrovirus Infections or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Deltaretrovirus Infections trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 5 |
| 2013 | 2 |
| 2012 | 1 |
| 2011 | 2 |
| 2009 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Deltaretrovirus Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 3 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 4 |
| Observational | 7 |
How many Deltaretrovirus Infections trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 18 |
| Terminated | 6 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Deltaretrovirus Infections trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 6 |
| MP Biomedicals, LLC | 3 |
| National Cancer Institute (NCI) | 3 |
| Kyowa Kirin Co., Ltd. | 1 |
| Tanabe Pharma Corporation | 1 |
Which drugs are being tested for Deltaretrovirus Infections? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Valproic acid, sodium salt | 3 |
| Lamivudine-Zidovudine (3TC-ZDV) | 1 |
| Positron Emission Tomography (PET) | 1 |
| Dolutegravir Pill | 1 |
| Interferon Alfa-2B | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Deltaretrovirus Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 4 | 2 |
| Hypercalcemia | 4 | 3 |
| Sepsis | 3 | 2 |
| Aspartate aminotransferase increased | 2 | 1 |
| Fever | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Deltaretrovirus Infections? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| New strain of human T lymphotropic virus (HTLV) type 3 in a Pygmy from Cameroon with peculiar HTLV serologic results. | The Journal of infectious diseases | 2009 | Yes |
| Simian T cell leukaemia virus type I subtype B in a wild-caught gorilla (Gorilla gorilla gorilla) and chimpanzee (Pan troglodytes vellerosus) from Cameroon. | The Journal of general virology | 2004 | Yes |
| Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. | The New England journal of medicine | 2004 | Yes |
| A novel, divergent simian T-cell lymphotropic virus type 3 in a wild-caught red-capped mangabey (Cercocebus torquatus torquatus) from Nigeria. | The Journal of general virology | 2003 | Yes |
| Molecular epidemiology of simian T-lymphotropic virus (STLV) in wild-caught monkeys and apes from Cameroon: a new STLV-1, related to human T-lymphotropic virus subtype F, in a Cercocebus agilis. | The Journal of general virology | 2001 | Yes |
Showing 5 of 18 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.